Glucose tolerance and somatostatin analog treatment in acromegaly: A 12-month study

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 8, 2009, Pages 2907-2914

  Colao, Annamaria ^a   Auriemma, Renata S ^a   Savastano, Silvia ^a   Galdiero, Mariano ^a   Grasso, Ludovica F S ^a   Lombardi, Gaetano ^a   Pivonello, Rosario ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GLYCOSYLATED HEMOGLOBIN; GROWTH HORMONE; INSULIN; LANREOTIDE AUTOGEL; METFORMIN; OCTREOTIDE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ACROMEGALY; ADULT; AGE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; FEMALE; GLUCOSE TOLERANCE; HORMONE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL;

EID: 68549122568     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-2627     Document Type: Article

References (41)

1. Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 25: 102-152
2. Nabarro JDN 1987 Acromegaly. Clin Endocrinol (Oxf) 26:481-512
3. Biering H, Knappe G, Gerl H, Lochs H 2000 Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Aust 27:27-31
4. Kreze A, Kreze-Spirova E, Mikulecky M 2001 Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 34:1429-1433
5. Colao A, Auriemma RS, Galdiero M, Cappabianca P, Cavallo LM, Esposito F, Grasso LFS, Lombardi G, Pivonello R 2008 Impact of somatostatin analogues versus surgery on glucose metabolism in acromegaly: results of a 5 years observational, open, prospective study. J Clin Endocrinol Metab 94:528-537
6. Pereira AM, Biermasz NR, Roelfsema F, Romijn JA 2005 Pharmacologic therapies for acromegaly. A review of their effects on glucose metabolism and insulin resistance. Treat Endocrinol 4:43-53
7. Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, Giavoli C, Ferrante E, Lania A, Spada A, Arosio M 2006 Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91: 121-128
8. Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, Cavallo LM, Esposito F, Lombardi G 2008 Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 93:2639-2646
9. Jørgensen JOL, Feldt-Rasmussen U, Frystyk J, Chen J-W, Kristensen LO, Hagen C, Ørskov H 2005 Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627-5631
10. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML 2005 Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90:5684-5691
11. Lamberts SW, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E 1985 Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 313:1576-1580
12. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N 2000 Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52:549-555
13. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D 2005 Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:4465-4473
14. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder K, Wass J, Giustina A, for the Acromegaly Treatment Consensus Workshop Participants 2002 Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054 - 4058.
15. Sheppard MC 2003 Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 58:387-399
16. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G 2006 Predictors of tumor shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 91:2112-2118
17. Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, Ghigo E and the participants of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous medical Education) Study Group 2006 J Endocrinol Invest 29:1017-1020
18. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529
19. 2007 AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13(Suppl 1): 1-68
20. Colao A, Marzullo P, Ferone D, Marinò V, Pivonello R, Di Somma C, Di Sarno A, Giaccio A, Lombardi G 1999 Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 22:40-47
21. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G 2001 Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779-2786
22. Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G 2005 Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clin Endocrinol (Oxf) 63:342-349
23. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G 2007 Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 157:579-587
24. Colao A, Auriemma RS, Rebora A, Galdiero M, Resmini E, Minuto F, Lombardi G, Pivonello R, Ferone D, Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogues naive patients with acromegaly. Clin Endocrinol (Oxf), 2008 Dec 15 [Epub ahead of print]
25. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW 2003 American College of Endocrinology Position Statement on the insulin resistance syndrome. Endocr Pract 9:240-252
26. Chestnut RE, Quarmby V 2002 Evaluation of total IGF-I assay methods using samples from type I and type II diabetic patients. J Immunol Methods 259: 11-24
27. Luft R, Cerasi E, Hamberger CA 1967 Studies on the pathogenesis of diabetes in acromegaly. Acta Endocrinol (Copenh) 56:593-607
28. Sonksen PH, Greenwood FC, Ellis JP, Lowy C, Rutherford A, Nabarro JD 1967 Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J Clin Endocrinol Metab 27:1418-1430
29. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A 2000 Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193-199
30. McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G 2004 Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 53:495-499
31. Verschoor L, Lamberts SW, Uitterlinden P, Del Pozo E 1986 Glucose tolerance during long term treatment with a somatostatin analogue. BrMedJ 293:1327-1328
32. Quabbe HJ, Plockinger U 1989 Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. J Clin Endocrinol Metab 68 873-881
33. Ho KK, Jenkins AB, Furler SM, Borkman M, Chisholm DJ 1992 Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 36:271-279
34. Breidert M, Pinzer T, Wildbrett J, Bornstein SR, Hanefeld M 1995 Long-term effect of octreotide in acromegaly on insulin resistance. Horm Metab Res 27:226-230
35. Koop BL, Harris AG, Ezzat S 1994 Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 130:581-586
36. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G 1995 Effects of treatment with octreotide in acromegalic patients - a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 133: 430-439
37. Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M 2002 Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 25:502-507
38. Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J 2006 Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly Eur J Endocrinol 155: 73-78
39. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G 2003 Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 59:492-499
40. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A 2009 Effects of somatostatin analogs on glucose homeostasis: a meta-analysis of acromegaly studies. J Clin Endocrinol Metab 94:1500-1508
41. Diabetes Prevention Program Research Group 2003 Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 26:977-980